PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
Portfolio Pulse from Lara Goldstein
PharmaTher Holdings (OTCQB:PHRRF) and the Terasaki Institute for Biomedical Innovation have reported positive outcomes from their research on a novel microneedle patch for the delivery of DMT. The study aimed to develop a suitable prototype of PharmaPatch for DMT’s transdermal delivery. The company will work with its research partner PharmaDrug Inc., and invest $227,700 in PharmaDrug's subsidiary, Sairiyo Therapeutics, for a 49% ownership.
July 18, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PharmaTher's positive outcomes from the DMT patch research and its investment in Sairiyo Therapeutics could potentially boost its stock.
The positive outcomes from the DMT patch research indicate that PharmaTher is making progress in its product development, which could attract investor interest. Additionally, its investment in Sairiyo Therapeutics could open up new opportunities for the company, potentially leading to a rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100